Idiopathic multicentric Castleman disease : An update in diagnosis and treatment advances
Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved..
Idiopathic multicentric Castleman disease (iMCD) is a rare disease, and it is likely underdiagnosed because of the heterogeneity of clinical manifestations and laboratory findings. While the disease leads to significant morbidity and mortality, its causes are not yet fully elucidated. There have been significant advances in diagnosis and treatment of iMCD in the past decade, including the approval of the anti-IL-6 antibody siltuximab. In this review, we provide an update of the many new developments and publications surrounding iMCD.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:64 |
|---|---|
| Enthalten in: |
Blood reviews - 64(2024) vom: 12. März, Seite 101161 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lang, Evan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
IL-6 |
|---|
| Anmerkungen: |
Date Completed 12.03.2024 Date Revised 12.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.blre.2023.101161 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365784508 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365784508 | ||
| 003 | DE-627 | ||
| 005 | 20240312233446.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.blre.2023.101161 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1324.xml |
| 035 | |a (DE-627)NLM365784508 | ||
| 035 | |a (NLM)38087716 | ||
| 035 | |a (PII)S0268-960X(23)00131-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lang, Evan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Idiopathic multicentric Castleman disease |b An update in diagnosis and treatment advances |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.03.2024 | ||
| 500 | |a Date Revised 12.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a Idiopathic multicentric Castleman disease (iMCD) is a rare disease, and it is likely underdiagnosed because of the heterogeneity of clinical manifestations and laboratory findings. While the disease leads to significant morbidity and mortality, its causes are not yet fully elucidated. There have been significant advances in diagnosis and treatment of iMCD in the past decade, including the approval of the anti-IL-6 antibody siltuximab. In this review, we provide an update of the many new developments and publications surrounding iMCD | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a IL-6 | |
| 650 | 4 | |a Idiopathic multicentric Castleman disease | |
| 650 | 4 | |a Siltuximab | |
| 700 | 1 | |a van Rhee, Frits |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Blood reviews |d 1995 |g 64(2024) vom: 12. März, Seite 101161 |w (DE-627)NLM013343343 |x 1532-1681 |7 nnns |
| 773 | 1 | 8 | |g volume:64 |g year:2024 |g day:12 |g month:03 |g pages:101161 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.blre.2023.101161 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 64 |j 2024 |b 12 |c 03 |h 101161 | ||